Medicare GLP-1 Bridge Tops 500,000 Users in Its First Two Months

The U.S. Medicare program is paying for GLP-1 medicines used only for weight loss for the first time. The Medicare GLP-1 Bridge, an 18-month demonstration that opened on 1 July 2026, signed up more than 500,000 beneficiaries in its first two months, the White House reported on 31 August. CMS Administrator Mehmet Oz put sign-ups at about 600,000. It is not a permanent Part D benefit, and it ends on 31 December 2027.

The program exists because federal law still bars Medicare from covering drugs used for weight loss. The November 2025 Most Favored Nation agreements with Eli Lilly and Novo Nordisk cut the government price to $245 a month and set a $50 patient copay, but the plan to run coverage through Part D plans, called BALANCE, stalled when plans refused the risk. CMS kept a transitional bridge and later extended it through the end of 2027.

A $245 price and a $50 copay

CMS pays manufacturers $245 per monthly supply, and beneficiaries pay a flat $50 copay at the pharmacy. The demonstration sits outside Part D coverage, so sponsors carry no risk and do not have to opt in. Humana, already the administrator of the LI NET program, is the single national processor for prior authorization, claims, and pharmacy payment.

Ad

The $50 copay does not fall under Extra Help, does not count toward the Part D deductible or the $2,100 out-of-pocket cap, and does not appear on the Part D explanation of benefits. The Medicare Prescription Payment Plan cannot spread it across the year. Coupons and discount cards cannot be stacked, and the program does not coordinate with other insurance.

Prior authorization requires a prescriber to attest that the drug is for weight reduction plus structured nutrition and activity. CMS says most early requests cleared in under 12 hours, with decisions mailed within 72 hours of a complete submission. Approval runs through 31 December 2027, including refills and dose changes, unless the patient switches GLP-1 products. There is no appeals process, though a prescriber can resubmit if the facts were wrong.

Who qualifies, and who does not

Covered products are Lilly’s Foundayo (orforglipron) tablets, Wegovy injection and tablets from Novo Nordisk, and Lilly’s Zepbound KwikPen only. Ozempic, Mounjaro, and Rybelsus stay in Part D for their other labeled uses.

To qualify, a beneficiary must be 18 or older, enrolled in an eligible Part D plan, and prescribed a covered product solely to reduce or maintain body weight. At the start of GLP-1 therapy they need a BMI of 35 or higher, or a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or stage 3a or worse chronic kidney disease, or a BMI of 27 or higher with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

The program is only for people who cannot get a GLP-1 through ordinary Part D. Anyone already filling a GLP-1 under Part D in 2026, or with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH with fibrosis, is steered back to Part D. That split creates a real mismatch: a patient with obesity plus diabetes can face a higher Part D copay than a neighbor who qualifies for the Bridge at $50.

Medicare GLP-1 Bridge: the uptake numbers

KFF estimated in June 2026 that 3.8 million Part D enrollees met the Bridge criteria in 2023, about 8% of Part D enrollment, after excluding people with diabetes, sleep apnea, or MASH and those already filling a GLP-1. Lilly has cited a much larger figure of roughly 20 million, which describes the broader clinical obesity burden in Medicare rather than the residual Bridge-only group.

Analysts are reading the early numbers as a demand signal. Jefferies analyst Akash Tewari, in a note reported by Fierce Pharma on 2 September, annualized the two-month print to $1.5 billion to $1.8 billion of manufacturer revenue at the $245 net price. He assigned $900 million to $1.2 billion of that to Lilly if its roughly 60% share of U.S. obesity volume carries into the program, and he said the run rate implies about 25% penetration of the eligible pool within another month or two, before growth slows. The implied fill rate works out to about 1.85 fills per enrollee over two months, which Tewari read as strong early adherence.

CVS and Walgreens each reported about 100,000 Bridge fills in late August. The White House cited $216 million in patient savings through 31 August.

What it means for Lilly, Novo, and the plans

For Lilly, the Bridge is incremental obesity volume in a population that had almost no coverage for Zepbound or Foundayo as weight-loss drugs, and the KwikPen-only rule funnels demand into a single device. Chief executive David Ricks has said the program added coverage for 35% more people for the company’s obesity portfolio. For Novo, Wegovy injection and tablets are in, but Ozempic stays in Part D, so the company cannot use the program to convert off-label Ozempic use.

Part D plans get a year-plus of utilization data without taking trend risk, which is why they accepted the Bridge after rejecting BALANCE. The open question for 2028 is whether CMS tries again to push obesity GLP-1s into the bid. IRA-negotiated prices for Ozempic, Rybelsus, and Wegovy, effective 2027, create a two-track price structure: obesity use at $245 against negotiated diabetes and cardiovascular use at different unit costs.

What to watch through 2027

KFF sketched the federal cost at $195 net per fill, which works out to about $1.3 billion over 18 months if 10% of the eligible pool participates and fills every month, rising to $3.3 billion at 25%, $6.7 billion at 50%, and $10 billion at 75%. Those are mechanical scenarios, not budget scores, and they assume continuous fills.

The numbers that matter next are whether the 600,000 sign-ups were a bolus or a run rate, how the Lilly versus Novo mix splits, and what adherence looks like at months six and twelve. A 2027 cliff will shape persistence marketing and any 2028 guidance manufacturers give investors. STAT has noted that a temporary obesity benefit is hard to turn off once several hundred thousand seniors are on $50 therapy, which makes the sunset in December 2027 the number to watch.